A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...

Pfizer has shared positive survival results from a late-stage study of its Braftovi (encorafenib) regimen in patients with ...

The data showed a surprisingly compelling overall survival (OS) benefit. TheBraftovi combination regimen received Food and ...

Pfizer Inc. announced statistically significant and clinically meaningful survival results from the phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

The world’s largest meeting on cancer research has brought promising updates on treatment and prevention for colorectal ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

In today’s Health Alert, new research on colorectal cancer shows that exercise and anti-inflammatory diets can boost survival ...